StockData

Lipocine vs Praxis Precision Medicines

LPCN and PRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LPCN and PRAX compare

Praxis Precision Medicines is the larger company, worth 633 times as much as Lipocine ($8.7B against $13.7M).

Lipocine scores higher on the StockData Score (9 against 7 for Praxis Precision Medicines), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLPCNPRAX
Size and price
Market cap$13.7M$8.7B
Share price$1.66$310.27
Change, 1 year−41.1%74.2%
Change, 5 years−91.4%23.4%
Beta (5Y)−0.431.90
Employees14168
StockData Score
Total score9 (better)7
Valuation score3 (better)0
Growth score1 (better)0
Performance score01 (better)
Health score56 (better)
Dividend score00
Valuation
P/S8.7×–
P/B0.6× (better)6.5×
FCF yield–−3.5%
Fair value$2.62–
Margin of safety36.5%–
Growth
Revenue growth (TTM)−62.7%–
Profitability
Operating margin−801%–
Net margin−755%–
Return on equity−60.9%−38.9% (better)
Financial health
Debt / equity0.000.00
Current ratio11.4815.73 (better)
Altman Z-score−9.28104.35 (better)
Piotroski F-score13 (better)
Dividends and buybacks
Buyback yield−119%–
Shareholder yield−119%0.00% (better)
Ownership
Held by institutions36.2%121%
Held by insiders9.0%0.72%
Insider net buying, 12 months$596K (better)−$3.6M
Short interest, % of float4.3%15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.